What is 23andMe's stock forecast?

23andMe (ME) stock soared 21 percent on its public market debut. Its SPAC merger with VG Acquisition (VGAC) gave the genetic testing company an enterprise value of $3.5 billion. What is 23andMe's stock forecast, and how high can it go?

What is 23andMe's equity value?

The SPAC merger gave 23andMe an equity value of $4.45 billion, and its stock surge boosted its equity value to around $5.92 billion. After adjusting for its $984 million in pro forma net cash, we get an EV (enterprise value) of around $4.9 billion. 23andMe’s 2024 price-to-sales multiple is 14.8x, and its 2024 EV-to-sales multiple is around 12.3x.

Is 23andMe Holding Co - Class A stock a good investment?

According to our live Forecast System, 23andMe Holding Co - Class A stock is a bad long-term (1-year) investment*. "ME" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "ME" projections.

What is the upside for 23andMe (23andMe)?

According to analysts' consensus price target of $5.60, 23andMe has a forecasted upside of 145.6% from its current price of $2.28. 23andMe has received no research coverage in the past 90 days. 23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics.